ROSE-010 / Rose Pharma - LARVOL DELTA

The Effect of the GLP-1 Agonist ROSE-010 on Food Consumption in Subjects with Overweight and Obesity (OBESITY WEEK 2025) - "The results suggest that ROSE-010 taken prior to meals in subjects with overweight and obesity may aid long term weight maintenance and weight loss when coupled with recommended dietary and health advice. In particular, the reduced period of nausea compared to long acting GLP-1 agonists may aid adherence and persistence in treatment of subjects with low tolerance of continuous GLP-1 exposure and its side effects."

Clinical • Genetic Disorders • Obesity

Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects (clinicaltrials.gov) - P2 | N=40 | Completed | Sponsor: Rose Pharma Inc | Not yet recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Improvement of irritable bowel syndrome with glucagon like peptide-1 receptor agonists: a systematic review and meta-analysis. (PubMed, Front Endocrinol (Lausanne)) - "GLP-1 and its analog ROSE-010 have been shown to inhibit the migrating motor complex and decrease gastrointestinal motility in IBS patients...Further investigation is needed to understand its impact on different IBS subtypes and long-term effects. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024613545."

Clinical • Journal • Retrospective data • Review • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

The Role of Glucagon-Like Peptide-1 Agonists on Gastric Emptying Measured by Scintigraphy Imaging (ACG 2024) - "Search words included ("GLP1 agonists" OR "GLP-1 analog" OR "liraglutide" OR "semaglutide" OR "exenatide" OR "lixisenatide" OR "albiglutide" OR "dulaglutide" OR "Tirzepatide") AND ("Gastric emptying" OR "residual gastric food" OR "residual gastric content*"). We identified 10 studies on scintigraphy imaging in patients on GLP-1 agonists.(Table-1) There were 239 patients 144 patients on GLP-1 and 141 patients on placebo. The medications used were Exenatide (5), liraglutide (2), semaglutide (1), ROSE-010 (1), GLP-1 (7–36)amide (1). The commonest indication for usage was obesity, Type 2 DM."

Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

A Randomized Controlled Clinical Trial of the GLP-1 Agonist ROSE-010 in Appetite Reduction (OBESITY WEEK 2024) - "Background: Clinical studies on long acting GLP-1 agonists such as semaglutide and tirzepatide have shown significant benefits in promoting weight loss in people with obesity and overweight. The results suggest that ROSE-010 may have potential in appetite control at mealtimes in subjects with overweight and obesity as an aid to weight control in addition to nutrition advice and education. The reduced period of nausea compared to long acting GLP-1 agonists may aid adherence to long term treatment."

Clinical • Genetic Disorders • Obesity